Aglycin ameliorates nonalcoholic fatty liver disease through modulation of the gut microbiota, restoration of the intestinal barrier, and inhibition of hepatic inflammation in mice
Food & Function · 2025
DOI: 10.1039/d5fo03751d ↗Kurz gefasst
Fachartikel in der Zeitschrift Food & Function, 2025. Verfasst von Leyan Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. …. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Soybean Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Aglycin alleviates NAFLD by modulating gut microbiota composition, restoring intestinal barrier function, and reducing hepatic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Food Hygiene, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China. zhaomin1986zm@126.com.
- School of Public Health, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, 250117, Shandong, China.
- College of Food Science and Engineering, Northwest A&F University, Yangling, 712100, Shaanxi, China.
- Zhong Shi Du Qing (Shandong) Biotechnology Company, Heze, 274108, Shandong, China.
- Center for Experimental Public Health and Preventive Medicine Education, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China.
- Nutrilite Health Institute, Shanghai, 201203, China. Hudson.wu@amway.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
Zitieren
APA
Zhou, L., Li, J., Wei, W., Ma, X., Xu, Z., Ouyang, L., Guan, Y., Jia, X., Wu, Q., & Zhao, M. (2025). Aglycin ameliorates nonalcoholic fatty liver disease through modulation of the gut microbiota, restoration of the intestinal barrier, and inhibition of hepatic inflammation in mice. Food & Function. https://doi.org/10.1039/d5fo03751d
Vancouver
Zhou L, Li J, Wei W, Ma X, Xu Z, Ouyang L, et al. Aglycin ameliorates nonalcoholic fatty liver disease through modulation of the gut microbiota, restoration of the intestinal barrier, and inhibition of hepatic inflammation in mice. Food & Function. 2025. doi:10.1039/d5fo03751d
BibTeX
@article{Zhou2025,
author = {Zhou, Leyan and Li, Juan and Wei, Wei and Ma, Xiaomin and Xu, Zhuyan and Ouyang, Limin and Guan, Yutong and Jia, Xue and Wu, Qiming and Zhao, Min},
title = {Aglycin ameliorates nonalcoholic fatty liver disease through modulation of the gut microbiota, restoration of the intestinal barrier, and inhibition of hepatic inflammation in mice},
journal = {Food & Function},
year = {2025},
doi = {10.1039/d5fo03751d}
}
EUVIMED